Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 5/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 7/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | GOT1 | P17174 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220805 | 0.85 | DRD2 (0.63) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL4306478 | 0.83 | ADRB1 (0.69) | DRD2DRD4DRD3GAAMAPT | |
| Hydrochloric Acid SCHEMBL5698349 | 0.81 | ADRB1 (0.67) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL23102103 | 0.79 | DRD2 (0.68) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL7220048 | 0.78 | DRD2 (0.60) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL27542561 | 0.77 | DRD2 (0.50) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL7732059 | 0.77 | DRD2 (0.69) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL5113532 | 0.77 | DRD2 (0.65) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL7534110 | 0.77 | DRD2 (0.65) | DRD2DRD4DRD3GAAMAPT | |
| SCHEMBL6197936 | 0.75 | DRD2 (0.57) | DRD2DRD4DRD3GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | claimed |
| EP-1140838-A1 | 1, 4-PIPERAZINE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010014680-A1 | 1,4-piperazine derivatives | WYETH | 2001-08-16 | — | — | US | claimed |
| US-6255302-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | claimed |
| WO-2000035878-A1 | 1,4-PIPERAZINE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-22 | — | — | WO | claimed |
| EP-1140838-A1 | 1, 4-PIPERAZINE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010014680-A1 | 1,4-piperazine derivatives | WYETH | 2001-08-16 | — | — | US | disclosed |
| US-6255302-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| WO-2000035878-A1 | 1,4-PIPERAZINE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014680-A1 | 1,4-piperazine derivatives | ADH1A, ADH1C, SNCA | DRD2 12/4885DRD4 26/4885DRD3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.